Trevor Moody Biography and Net Worth

Director of electroCore

Trevor is a Partner at M.H. Carnegie & Co, an Australian private equity and venture capital firm. He is also President of TM Strategic Advisors LLC, a management consultancy serving the boards, investors, and senior management of both emerging and established medical technology companies. Trevor brings significant experience, with over 25 years in the development, commercialization, and funding of innovative growth-oriented medical technologies. He was previously a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with over $3 billion under management. Trevor co-led the medical device team at Frazier and became known as an active and well-regarded investor. In addition to several private boards, Trevor is the previous Board Chair of the Center for Infectious Disease Research, one of the largest independent non-profit research institutes focused on diseases of the developing world.

Trevor graduated from the Massachusetts Institute of Technology with a Master of Science in Management (Sloan School) and the University of Southern Queensland, Australia, with a Bachelor of Engineering. Trained as a biomedical engineer with an electrical focus, Trevor held product development and product marketing roles at Telectronics Pacing Systems and Ventritex, both in the cardiac rhythm management market.

What is Trevor J. Moody's net worth?: The estimated net worth of Trevor J. Moody is at least $390,881.46 as of May 27th, 2022. Mr. Moody owns 25,598 shares of electroCore stock worth more than $390,881 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Moody may own. Learn More about Trevor J. Moody's net worth.
How do I contact Trevor J. Moody?: The corporate mailing address for Mr. Moody and other electroCore executives is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. electroCore can also be reached via phone at (973) 290-0097 and via email at [email protected]. Learn More on Trevor J. Moody's contact information.
Has Trevor J. Moody been buying or selling shares of electroCore?: Trevor J. Moody has not been actively trading shares of electroCore in the last ninety days. Most recently, on Tuesday, May 31st, Trevor J. Moody bought 2,631 shares of electroCore stock. The stock was acquired at an average cost of $6.60 per share, with a total value of $17,364.60. Following the completion of the transaction, the director now directly owns 28,230 shares of the company's stock, valued at $186,318. Learn More on Trevor J. Moody's trading history.
Who are electroCore's active insiders?: electroCore's insider roster includes Thomas Errico (Director), John Gandolfo (Director), Daniel Goldberger (CEO), Trevor Moody (Director), and Brian Posner (CFO). Learn More on electroCore's active insiders.
Are insiders buying or selling shares of electroCore?: During the last year, electroCore insiders bought shares 3 times. They purchased a total of 44,505 shares worth more than $284,617.15. The most recent insider tranaction occured on August, 15th when Director Thomas J Errico bought 5,000 shares worth more than $30,600.00. Insiders at electroCore own 19.7% of the company. Learn More about insider trades at electroCore.
Information on this page was last updated on 8/15/2024.

Trevor J. Moody Insider Trading History at electroCore

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2022	Buy	2,631	$6.60	$17,364.60	28,230
5/27/2022	Buy	701	$6.45	$4,521.45	25,598
7/2/2021	Buy	6,666	$15.00	$99,990.00	24,897

Trevor J. Moody Buying and Selling Activity at electroCore

electroCore Company Overview

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Today's Range

Now: $15.27

$14.27

$16.20

50 Day Range

MA: $11.66

$7.83

$15.47

2 Week Range

Now: $15.27

$5.25

$17.84

Volume

198,723 shs

Average Volume

37,439 shs

Market Capitalization

$100.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.